Shannon Westin

Shannon Westin, MD, MPH, FACOG is Professor and Section Chief of Gynecologic Oncology at MD Anderson Cancer Center, where she co-directs the GYN Cancer Moon Shot Program and leads the Uterine Cancer Program. She is one of the most prolific gynecologic oncology clinical investigators in North America, with a research program centered on developing novel targeted therapies for endometrial, ovarian, and cervical cancers. Dr. Westin is internationally recognized for her pioneering work with WEE1 kinase inhibitors in gynecologic malignancies — she led the landmark phase II trial of adavosertib (AZD1775) in recurrent uterine serous carcinoma, demonstrating meaningful single-agent activity and establishing WEE1 as a therapeutic vulnerability in p53-mutant gynecologic tumors. She has also led or co-led phase I/II trials examining PARP inhibitors (olaparib, niraparib, rucaparib) combined with targeted agents including temozolomide, PI3K/mTOR inhibitors, and immune checkpoint inhibitors in endometrial and ovarian cancers. Dr. Westin is deeply engaged with NRG Oncology and the GOG Foundation, co-leading multiple cooperative group trials, and has been a central contributor to molecularly stratified endometrial cancer trials exploiting The Cancer Genome Atlas (TCGA) four-subtype classification. She holds editorial positions at major gynecologic oncology journals and is an active mentor developing the next generation of gynecologic oncology investigators.